MannKind | Spese Operative



Operating Expenses Cambiamento Data
Adma Biologics USD 80.47M 268K 2024-12
Dynavax Technologies USD 73.66M 3.12M 2024-12
Eli Lilly USD 8.38B 1.53B 2024-12
Halozyme Therapeutics USD 122.51M 4.38M 2024-12
Insmed USD 334.86M 28M 2024-12
MacroGenics USD 56.52M 12.46M 2024-09
MannKind USD 63.68M 11.62M 2024-12
Merck USD 11.33B 1.4B 2024-12
Novo Nordisk DKK 37.49B 4.64B 2024-09
Pfizer USD 18.17B 5.63B 2024-12
Sanofi EUR 10.07B 969M 2024-09
Xencor USD 65.97M 7.02M 2024-12



MannKind Spese Operative - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Mar 2025.